NCT04653194View on ClinicalTrials.gov

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

July 30, 2023

Study Completion Date

July 31, 2023

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Biktarvy

Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg

DRUG

Symtuza

Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg

Trial Locations (3)

BN2 5BE

Brighton and Sussex University Hospitals NHS Trust Lawson Unit Royal Sussex County Hospital, Brighton

SW10 9NH

Chelsea and Westminster Hospital NHS Foundation Trust, London

Unknown

Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Imperial College London

OTHER

collaborator

Gilead Sciences

INDUSTRY

lead

Chelsea and Westminster NHS Foundation Trust

OTHER